Dermatological Disorders, Drugs in the Pipeline
Dupilumab Gets Priority Review for Atopic Dermatitis in Patients Aged 6 to 11 Years
Dupixent, an interleukin-4 receptor alpha antagonist, is currently approved for moderate to severe atopic dermatitis in patients ≥12 years old who are not adequately controlled with topical prescription therapies or when they are not advisable.
